Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This
Author: Tamas Sohajda
Cyclolab R&D Director
UK grants early access for Gilead’s remdesivir in Covid-19
The government of the U.K. is granting the country’s equivalent to an emergency use authorization to remdesivir, the antiviral drug
First copies of Gilead’s SBECD-enabled remdesivir to start selling in Bangladesh
According to Hindustan Times, Bangladesh’s Beximco Pharmaceuticals Ltd. has become the world’s first company to start selling the generic version
Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand
Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
Japan approved the Gilead Sciences antiviral drug remdesivir Thursday for treatment of severe COVID-19 patients, under an exceptional approval pathway
UC Berkeley, Excivion and CycloLab develop antiviral cyclodextrins against SARS-CoV-2
UC Berkeley, Excivion and Cyclolab announce a supplemental grant awarded to UC Berkeley by the National Institutes of Health to evaluate a wide
Gilead outlines plans to distribute COVID-19 drug worldwide
Gilead on Tuesday said it is negotiating with overseas drug manufacturers to license its SBECD-enabled coronavirus treatment remdesivir in an effort
Az amerikai gyógyszerhatóság (FDA) engedélyezte a ciklodextrinnel formulázott remdesivir használatát COVID-19 kezelésére
A Gilead Sciences, Inc. amerikai gyógyszercég tegnap bejelentette, hogy a U.S. Food and Drug Administration (FDA, amerikai gyógyszerhatóság) úgynevezett “emergency
SBECD-enabled Remdesivir Receives FDA’s Emergency Use Authorization for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for
Gilead’s Remdesivir meets main goal of trial in COVID-19 patients
Gilead Sciences today announced that preliminary results of a coronavirus drug trial showed at least 50% of patients treated with